University of Mississippi Medical Center
umc.eduTotal trials
125
Active
15
Phase 3
10
Total enrollment
12,709
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 17 OHPC | — | — | — | — | — | 1 | |
| Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing | — | — | — | — | — | 1 | |
| Empagliflozin 10 mg daily dosing | — | — | — | — | — | 1 | |
| Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen | — | — | — | — | — | 1 | |
| Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-05-04
- 2027-01-31
Top conditions
- Hypertension8
- Obesity7
- Asthma4
- Sickle Cell Disease4
- Spinal Cord Injuries3
- Preeclampsia3
- Sedentary Behavior3
- PreDiabetes2
Frequently asked questions about University of Mississippi Medical Center
- How many clinical trials does University of Mississippi Medical Center have on ClinicalTrials.gov?
- University of Mississippi Medical Center is listed as the lead sponsor on 125 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Mississippi Medical Center's trials are in Phase 3?
- 10 of University of Mississippi Medical Center's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does University of Mississippi Medical Center focus on?
- University of Mississippi Medical Center's most-studied conditions on ClinicalTrials.gov are Hypertension, Obesity, Asthma, Sickle Cell Disease, Spinal Cord Injuries.
- When are University of Mississippi Medical Center's next clinical trial readouts?
- University of Mississippi Medical Center has 3 upcoming primary-completion readouts tracked here; the soonest is “Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury”, expected around 2025-12-31.